CDA | Evidence Driven
CDA | Evidence Driven

olopatadine hydrochloride and mometasone

Details

Files
Generic Name:
olopatadine hydrochloride and mometasone
Project Status:
Active
Therapeutic Area:
Seasonal allergic rhinitis
Manufacturer:
Bausch Health
Call for patient/clinician input open:
Brand Name:
Ryaltris
Project Line:
Reimbursement Review
Project Number:
SR0848-000
Call for patient/clinician input closed:
NOC Status at Filing:
Post NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
Ryaltris (olopatadine hydrochloride and mometasone furoate nasal spray) is indicated for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
Key Milestones2
Call for patient/clinician input open10-May-24
Call for patient/clinician input closed08-Jul-24
Submission received21-Jun-24
Submission accepted08-Jul-24
Review initiated09-Jul-24
Draft CADTH review report(s) provided to sponsor for comment26-Sep-24
Deadline for sponsors comments08-Oct-24
CADTH review report(s) and responses to comments provided to sponsor15-Nov-24
Expert committee meeting (initial)27-Nov-24
Draft recommendation issued to sponsorDecember 09, 2024
To
December 11, 2024
Draft recommendation posted for stakeholder feedback19-Dec-24
End of feedback period10-Jan-25

Files

Patient and Clinician Group input View PDF
Last Updated : November 15, 2024